Shopping Cart 0
Cart Subtotal
AED 0

Vectura Group Plc (VEC) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

Vectura Group Plc (VEC)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vectura Group Plc (Vectura) is a formulation, device design and development company. It focuses on inhaled airways products through an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on proprietary lung delivery technologies. It has partnership and license agreement with other global biotechnology and pharmaceutical companies to develop portfolio of drugs including inhaled in-market products and inhaled generics. Vectura is headquartered in Chippenham, Wiltshire, the UK.

Vectura Group Plc Key Recent Developments

Jun 10,2019: Vectura Group announces leadership changes

May 04,2019: Vectura wins US GSK Patent Litigation and awarded USD 89.7Million in damages by Trial Jury

Apr 01,2019: Vectura Group names Kevin Matthews to its board of directors

Mar 26,2019: Vectura Group 2018 preliminary results

Dec 13,2018: Update on UK GSK patent litigation

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Vectura Group Plc-Key Facts

Vectura Group Plc-Key Employees

Vectura Group Plc-Key Employee Biographies

Vectura Group Plc-History

Vectura Group Plc-Company Statement

Vectura Group Plc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Vectura Group Plc-Business Description

Geographical Segment: Switzerland

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Rest of Europe

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: United Kingdom

Performance

Geographical Segment: United States of America

Performance

Vectura Group Plc-Corporate Strategy

Vectura Group Plc-SWOT Analysis

SWOT Analysis-Overview

Vectura Group Plc-Strengths

Vectura Group Plc-Weaknesses

Vectura Group Plc-Opportunities

Vectura Group Plc-Threats

Vectura Group Plc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Vectura Group Plc, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 10, 2019: Vectura Group announces leadership changes

May 04, 2019: Vectura wins US GSK Patent Litigation and awarded USD 89.7Million in damages by Trial Jury

Apr 01, 2019: Vectura Group names Kevin Matthews to its board of directors

Mar 26, 2019: Vectura Group 2018 preliminary results

Dec 13, 2018: Update on UK GSK patent litigation

Nov 09, 2018: Vectura and Hikma to jointly develop generic versions of GSK's Ellipta

Oct 31, 2018: Vectura Group: Directorate change

Oct 22, 2018: Vectura group has announced the board change

Sep 11, 2018: Vectura Group: Interim Results

Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Vectura Group Plc, Performance Chart (2014-2018)

Vectura Group Plc, Ratio Charts

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Vectura Group Plc, Key Facts

Vectura Group Plc, Key Employees

Vectura Group Plc, Key Employee Biographies

Vectura Group Plc, History

Vectura Group Plc, Subsidiaries

Vectura Group Plc, Key Competitors

Vectura Group Plc, Ratios based on current share price

Vectura Group Plc, Annual Ratios

Vectura Group Plc, Annual Ratios (Cont...1)

Vectura Group Plc, Annual Ratios (Cont...2)

Vectura Group Plc, Interim Ratios

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Vectura Group Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Vectura Group Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Theravance Biopharma UK Ltd

Consort Medical Plc

AstraZeneca Plc

Aerogen Ltd

Company Profile

Company Profile Title

Vectura Group Plc (VEC)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vectura Group Plc (Vectura) is a formulation, device design and development company. It focuses on inhaled airways products through an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on proprietary lung delivery technologies. It has partnership and license agreement with other global biotechnology and pharmaceutical companies to develop portfolio of drugs including inhaled in-market products and inhaled generics. Vectura is headquartered in Chippenham, Wiltshire, the UK.

Vectura Group Plc Key Recent Developments

Jun 10,2019: Vectura Group announces leadership changes

May 04,2019: Vectura wins US GSK Patent Litigation and awarded USD 89.7Million in damages by Trial Jury

Apr 01,2019: Vectura Group names Kevin Matthews to its board of directors

Mar 26,2019: Vectura Group 2018 preliminary results

Dec 13,2018: Update on UK GSK patent litigation

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Vectura Group Plc-Key Facts

Vectura Group Plc-Key Employees

Vectura Group Plc-Key Employee Biographies

Vectura Group Plc-History

Vectura Group Plc-Company Statement

Vectura Group Plc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Vectura Group Plc-Business Description

Geographical Segment: Switzerland

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Rest of Europe

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: United Kingdom

Performance

Geographical Segment: United States of America

Performance

Vectura Group Plc-Corporate Strategy

Vectura Group Plc-SWOT Analysis

SWOT Analysis-Overview

Vectura Group Plc-Strengths

Vectura Group Plc-Weaknesses

Vectura Group Plc-Opportunities

Vectura Group Plc-Threats

Vectura Group Plc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Vectura Group Plc, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 10, 2019: Vectura Group announces leadership changes

May 04, 2019: Vectura wins US GSK Patent Litigation and awarded USD 89.7Million in damages by Trial Jury

Apr 01, 2019: Vectura Group names Kevin Matthews to its board of directors

Mar 26, 2019: Vectura Group 2018 preliminary results

Dec 13, 2018: Update on UK GSK patent litigation

Nov 09, 2018: Vectura and Hikma to jointly develop generic versions of GSK's Ellipta

Oct 31, 2018: Vectura Group: Directorate change

Oct 22, 2018: Vectura group has announced the board change

Sep 11, 2018: Vectura Group: Interim Results

Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Vectura Group Plc, Performance Chart (2014-2018)

Vectura Group Plc, Ratio Charts

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Vectura Group Plc, Key Facts

Vectura Group Plc, Key Employees

Vectura Group Plc, Key Employee Biographies

Vectura Group Plc, History

Vectura Group Plc, Subsidiaries

Vectura Group Plc, Key Competitors

Vectura Group Plc, Ratios based on current share price

Vectura Group Plc, Annual Ratios

Vectura Group Plc, Annual Ratios (Cont...1)

Vectura Group Plc, Annual Ratios (Cont...2)

Vectura Group Plc, Interim Ratios

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Vectura Group Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Vectura Group Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Theravance Biopharma UK Ltd

Consort Medical Plc

AstraZeneca Plc

Aerogen Ltd